The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Global Emergence of Trimethoprim/Sulfamethoxazole Resistance in Stenotrophomonas maltophilia Mediated by Acquisition of sul Genes
Open accessAbstract
Trimethoprim/sulfamethoxazole (TMP/SMX) resistance remains a serious threat in the treatment of Stenotrophomonas maltophilia infections.We analyzed an international collection of 55 S. maltophilia TMP/SMX-sensitive (S) (n = 30) and -resistant (R) (n = 25) strains for integrons; sul1, sul2 and dhfr genes; and insertion element common region (ISCR) elements.sul1, as part of a class 1 integron, was detected in 17 of 25 TMP/SMX-R.Nine TMP/SMX-R strains carried sul2; 7 were on large plasmids.Five TMP/SMX-R isolates were positive for ISCR2, and 4 were linked to sul2; 2 others possessed ISCR3.Two ISCR2s were adjacent to floR.Six TMP/SMX-S isolates harbored novel ISCR elements, ISCR9 and ISCR10.Linkage of ISCR3, ISCR9, and ISCR10 to sul2 and dhfr genes was not demonstrated.The data from this study indicate that class 1 integrons and ISCR elements linked to sul2 genes can mediate TMP/SMX resistance in S. maltophilia and are geographically widespread, findings that reinforce the need for ongoing resistance surveillance.N osocomial Stenotrophomonas maltophilia are intrinsi- cally resistant to a plethora of antimicrobial agents that severely limit commonly used empiric standard antimicrobial therapies.S. maltophilia is resistant to many β-lactams, β-lactamase inhibitors, and aminoglycosides (1,2).A recent survey of SENTRY (www.jmilabs.com)Antimicrobial Surveillance Program isolates indicated that the newer fluoroquinolones demonstrated good efficacy; the most active were levofloxacin (6.5% resistance) and gatifloxacin (14.1%) (3).Furthermore, the resistance to the polymyxins (20%-32%) is higher than observed in Pseudomonas aeruginosa (3,4).Because of low resistance levels (≈5%), trimethoprim/sulfamethoxazole (TMP/ SMX) remains the therapy of choice worldwide.A recent study encompassing data from Europe, Latin America, and North America indicates that the level of resistance to TMP/SMX is 3.8%; however, previous studies indicate that the level is higher in Latin America than North America (5,6).Although surveillance studies are few, resistance to TMP/SMX appears to be emerging, and recent in vitro modeling studies have shown that combination therapies of TMP/SMX plus ciprofloxacin and TMP/SMX plus tobramycin exhibit a greater killing capacity then TMP/SMX alone (7,8).S. maltophilia exhibits an array of mechanisms that singularly or collectively contribute to its multidrug resistance status.Intrinsic resistance includes inducible efflux pumps (2) and multiple β-lactamase expression (1) but not mutations in the quinolone resistance-determining region (9).In addition, S. maltophilia can acquire resistance through integrons, transposons, and plasmids (10).Recently, class 1 integrons have been characterized from S. maltophilia strains isolated in Argentina and Taiwan, which indicates that they contribute to TMP/SMX resistance through the sul1 gene carried as part of the 3′ end of the class 1 integron (10).In addition to class 1 integrons, other mobile elements are associated with sul genes.For example, Vibrio cholerae serogroup 0139 is resistant to several antimicrobial agents, including SMX, and it has been recently shown that the sul2 gene was part of a cluster located on a novel genetic Global Emergence of Trimethoprim/Sulfamethoxazole Resistance in Stenotrophomonas maltophilia Mediated by Acquisition of sul Genes
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Beaber, J. W., Hochhut, B., & Waldor, M. K. (2002) · Journal of Bacteriology · doi:10.1128/jb.184.15.4259-4269.2002 · Cited by 248
Cited by
Stenotrophomonas maltophilia: an Emerging Global Opportunistic Pathogen
Brooke, J. S. (2012) · Clinical Microbiology Reviews · doi:10.1128/cmr.00019-11 · Cited by 1,434
The versatility and adaptation of bacteria from the genus Stenotrophomonas
Ryan, R. P., Monchy, S., Cardinale, M., Taghavi, S., Crossman, L., Avison, M. B., Berg, G., van der Lelie, D., & Dow, J. M. (2009) · Nature Reviews Microbiology · doi:10.1038/nrmicro2163 · Cited by 873
Tamma, P. D., Aitken, S. L., Bonomo, R. A., Mathers, A. J., van Duin, D., & Clancy, C. J. (2023) · Clinical Infectious Diseases · doi:10.1093/cid/ciad428 · Cited by 740
Kristiansson, E., Fick, J., Janzon, A., Grabic, R., Rutgersson, C., Weijdegård, B., Söderström, H., & Larsson, D. G. J. (2011) · PLoS ONE · doi:10.1371/journal.pone.0017038 · Cited by 566
Chang, Y.-T., Lin, C.-Y., Chen, Y.-H., & Hsueh, P.-R. (2015) · Frontiers in Microbiology · doi:10.3389/fmicb.2015.00893 · Cited by 419
Metadata
- Authors
- Toleman, M. A., Bennett, P. M., Bennett, D. M. C., Jones, R. N., & Walsh, T. R.
- Venue
- Emerging Infectious Diseases
- Published
- 2007-04
- Volume
- 13
- Issue
- 4
- Pages
- 559-565
- ISSN
- 1080-6040 (ISSN-L)
- 1080-6059
- OpenAlex
- W2163206615
- Cited by
- 217
- References
- 1
- FWCI
- 5.29
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Global Emergence of Trimethoprim/Sulfamethoxazole Resistance in Stenotrophomonas maltophilia Mediated by Acquisition of sul Genes. https://app.cochat.ai/papers/10.3201/eid1304.061378
- The paper
- Toleman, M. A., Bennett, P. M., Bennett, D. M. C., Jones, R. N., & Walsh, T. R. (2007). Global Emergence of Trimethoprim/Sulfamethoxazole Resistance in Stenotrophomonas maltophilia Mediated by Acquisition of sul Genes. Emerging Infectious Diseases. https://doi.org/10.3201/eid1304.061378
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.